Argenx
| Type | Public |
|---|---|
| Industry | Biotechnology |
| Founded | 2008 |
| Headquarters | , |
Key people | Tim van Hauwermeiren, CEO Peter Verhaeghe, chairman |
| Revenue | €4.2 billion[1] (2025) |
| 792,700,000 euro (2024) | |
Number of employees | 1,863 |
| Website | www |
Argenx SE (Euronext Brussels: ARGX ) is a Belgian-Dutch pharmaceutical company specializing in immunology. Argenx specializes in the development of antibody therapies for the treatment of autoimmune diseases and cancer. Its work primarily focuses on the development of orphan drugs.
History
In 2008, Argenx, based in Ghent, was founded by three scientists: Tim Van Hauwermeiren, a former executive at Ablynx, and two of his colleagues, Hans de Haard and Torsten Dreier.[2] Their aim was to bring new drugs for the treatment of autoimmune diseases to the market. Through collaboration with researchers, including the scientist Sally Ward, they developed a new generation of medicines targeting Immunoglobulin G autoantibodies.[2]
In order to finance research, development, applications for marketing authorization and the commercialization of its medicines, the company was listed in the United States on the Nasdaq[3][4] and in Belgium on the Brussels Stock Exchange, where it was added to the BEL 20 in June 2018.[5]
In 2021, the company received marketing authorization from the United States Food and Drug Administration for its first medicine, Vyvgart (active substance: efgartigimod alfa), for the treatment of myasthenia gravis.[2][6]
In 2023, the company experienced two setbacks in attempts to broaden the indications for its flagship medicine Vyvgart: clinical studies for the treatment of immune thrombocytopenic purpura (ITP) and then pemphigus were inconclusive.[7][8]
In April 2025, the US FDA approved a prefilled syringe version of the company's immune disorder drug Vyvgart.[9]
In September 2025, Argenx was added to the Euro Stoxx 50 Index.[10][11]
References
- ^ "Annual Report 2025" (PDF). argenx. Retrieved 3 May 2026.
- ^ a b c Chaffin, Zeliha (24 October 2023). "Argenx, l'étoile montante de la biotech européenne". Le Monde (in French).
- ^ "Argen-X vaut-elle l'investissement? L'analyse complète". TransactionBourse (in French). 30 January 2018.
- ^ Pouget, Sacha (2 February 2021). "Argenx est l'exemple type d'une réussite Biotech européenne". Biotech Bourse (in French).
- ^ Mooijman, Ruben (5 June 2018). "Argen-X komt in BEL20". De Standaard (in Dutch).
- ^ Belga, Anne François (18 December 2021). "Argenx reçoit le feu vert pour commercialiser son premier traitement aux Etats-Unis". VRT News (in French).
- ^ "Argenx ne se remet pas en Bourse d'une chute historique dans l'histoire de la biotech". Les Echos (in French). 21 December 2023. Retrieved 21 December 2023.
- ^ Wuille, Stéphane (20 December 2023). "Deuxième échec en moins d'un mois pour argenx, le titre dégringole". L'Echo (in French). Retrieved 31 July 2025.
- ^ "US FDA approves syringe version of Argenx's immune disorder drug". Reuters. Archived from the original on 13 April 2025. Retrieved 18 November 2025.
- ^ "Euro Stoxx 50: Deutsche Bank und Siemens Energy steigen auf". FAZ.NET (in German). 2025-09-01. Retrieved 2026-05-14.
- ^ "Euro Stoxx 50 Adds Deutsche Bank, Siemens Energy, Argenx". Morningstar. 2 September 2025. Retrieved 18 November 2025.